PharmaShots | Incisive News in 3 Shots

Subscribe Now

novo nordisk

Novo Nordisk Highlights the Part 1 Results from P-III (ESSENCE) Study of Semaglutide to Treat MASH at AASLD 2024 - The Liver Meeting

Novo Nordisk Highlights the Part 1 Results from P-III (ESSENCE) Study of Semaglutide to Treat MASH at AASLD 2024 - The Liver Meeti...

November 20, 2024

Novo Nordisk Reports the Acquisition of Cardior Pharmaceuticals for ~$1.11B

Novo Nordisk Reports the Acquisition of Cardior Pharmaceuticals for ~$1.11B

March 26, 2024

Novo Nordisk’s Awiqli Receives the CHMP’s Positive Opinion for the Treatment of Diabetes

Novo Nordisk’s Awiqli Receives the CHMP’s Positive Opinion for the Treatment of Diabetes

March 21, 2024

Novo Nordisk to Acquire Ocedurenone from KBP Biosciences for ~$1.3B

Novo Nordisk to Acquire Ocedurenone from KBP Biosciences for ~$1.3B

October 17, 2023

PharmaShots Weekly Snapshots (October 03–06, 2023)

PharmaShots Weekly Snapshots (October 03–06, 2023)

October 7, 2023

Novo Nordisk’ Rivfloza (nedosiran) Receives the US FDA’s Approval for Children Aged ≥9 Years and Adults with Primary Hyperoxaluria Type 1

Novo Nordisk’ Rivfloza (nedosiran) Receives the US FDA’s Approval for Children Aged ≥9 Years and Adults with Primary Hyperoxaluria...

October 3, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us